🟢 HIMS is trading 4% up today on its generic semaglutide launch in Canada

HIMS is trading 4% up today at $23.96 following the launch of its generic semaglutide weight-loss offering in Canada.

• The move marks the company's first international expansion, with personalized plans starting at $149 CAD per month.
• The expansion provides a new growth pillar beyond U.S. telehealth services, tapping into the high-demand global weight-loss market.
• Shares are outperforming the broader market as investors react positively to the company's entry into the Canadian market.